Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Net Income	-74.88	-46.88
Depreciation & Amortization	0.17	0.17
Stock-Based Compensation	6.88	14.52
Other Adjustments	-2.19	0.05
Changes in Accounts Payable	-3.07	2.07
Changes in Accrued Expenses	3.95	0.92
Changes in Other Operating Activities	-8.81	-0.48
Operating Cash Flow	-77.94	-29.63
Capital Expenditures	-0.36	-0.11
Purchases of Investments	-396.39	-
Proceeds from Sale of Investments	212.5	-
Investing Cash Flow	-184.25	-0.11
Issuance of Common Stock	0	-
Net Common Stock Issued (Repurchased)	0	-
Issuance of Preferred Stock	-	326.1
Net Preferred Stock Issued (Repurchased)	-	326.1
Other Financing Activities	-0.87	13.2
Financing Cash Flow	-0.87	339.3
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0	-
Net Cash Flow	-263.06	309.55

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q